Sofía Castelli

Excited to see our work come to life!

Fueling CAR with IL-9 bit.ly/4ox164C  @msofiacastelli

IL-9, the little-known cytokine, finally found its calling, helping CAR T cells take on solid tumors. More staying power, more memory, more punch. #science #immunology cell.com/immunity/abstr…

New in @ImmunityCP: @msofiacastelli and a team in the @carlhjune lab engineered CAR T cells with IL-9 signaling to boost efficacy against #SolidTumors. bit.ly/48vJql0

IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy: Immunity ⁦@parkerici⁩ ⁦@PennMedicine⁩ cell.com/immunity/abstr…

@PennMedicine @PennMedCSO

This work highlights a promising strategy to improve CAR T therapies for solid cancers through IL-9 signaling. Grateful to my mentors, Carl June and Gina Young, as well as the rest of the authors for making this possible!

Check out our paper out today in Immunity! Paper link: cell.com/immunity/abstr… This work is the result of my PhD project in Dr. Carl June’s lab, and I’m incredibly proud to finally see it published.

Engineering T cells (CAR T) for treatment of solid cancers has had mixed success to date. Two reports today raise the promise of using interleukin-9 as a way to raise efficacy @ImmunityCP cell.com/immunity/fullt… cell.com/immunity/fullt…

Report of note: IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy •Engineering CAR T cells with IL-9 signaling boosts efficacy against solid tumors •IL-9-signaling CD4+ CAR T cells have increased Th1 and proliferative phenotypes •Single-cell profiling reveals that IL-9 redirects CD8+ T cell fate away from dysfunction •IL-9-induced STAT1/STAT4 activation contributes to improved CAR T cell function cell.com/immunity/fullt…

Online now: IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy dlvr.it/TPPKLL

IL-9 enhancement of engineered CAR-T therapies @ImmunityCP @carlhjune @msofiacastelli @Penn @xrtcell @stanford @KaylaKulhanek cell.com/immunity/fullt… cell.com/immunity/fullt…

🚨Coming soon! Multiplex engineering using microRNA-mediated gene silencing in CAR T cells. In a single lentiviral vector- multiplex silencing & expression of a CAR, better expansion & viability than gene editing by electroporation @PennMedicine antionbio.com @FrontiersIn frontiersin.org/journals/immun…

A next-generation “armored” CAR T cell therapy showed promising results in a small study of patients with B-cell lymphoma who had exhausted other treatment options ft. @carlhjune (@PennPathLabMed) & Jakub Svoboda (@PennCancer) @UPenn_I3H tinyurl.com/3ejw9334

Congratulations to our own Drs. June and Levine!

Penn researchers found that next-generation IL18-armored #CARTCellTherapy shows promise for patients whose #lymphoma resisted multiple other cancer treatments, including commercial CAR T cell therapies. @carlhjune @NEJM @AACR #NCRM #UnitedByCancerResearch spr.ly/6019NpiON

CAR T-cell therapy isn’t just a breakthrough—it’s a lifeline. A new PICI-supported review in @MolTherapy by @carlhjune, Director of the PICI Center at @PennMedicine, and team traces the decades of research that made engineered immune cells a powerful cancer treatment. cell.com/molecular-ther…

CAR T-cell therapy has transformed treatment for 35K+ patients, with a well-established safety profile. New in @TheLancet: @carlhjune, Director of the PICI Center at @PennMedicine, @BLLPHD & @daniel_baker_j explore latest data and what’s next in the field. thelancet.com/journals/lance…

Crystal Mackall and Carl June discussed groundbreaking strategies to enhance CAR T-cell therapies, pushing the boundaries for solid cancer treatment on day 3 of #AACRIO25. Learn more on the #AACRBlog: brnw.ch/21wR0gf @parkerici @PennMedicine

@Yo19940376 @carlhjune Thank you!!

@msofiacastelli @carlhjune Congrats!!!!

Excited to share my PhD thesis work with @CarlHJune now out as a preprint on bioRxiv! We show that engineering IL-9 signaling enhances CAR T cell antitumor efficacy by steering them toward potent memory and effector states. biorxiv.org/content/10.110…